Docoh
Loading...

GBT Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

GBT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

3 Aug 21
15 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 421.71M 421.71M 421.71M 421.71M 421.71M 421.71M
Cash burn (monthly) 8.67M (positive/no burn) 22.02M 21.26M 14.77M 5.97M
Cash used (since last report) 30.63M n/a 77.77M 75.08M 52.17M 21.08M
Cash remaining 391.07M n/a 343.93M 346.63M 369.53M 400.62M
Runway (months of cash) 45.1 n/a 15.6 16.3 25.0 67.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Oct 21 Johnson David Lee Common Stock Payment of exercise Dispose F No No 26.25 2,170 56.96K 39,072
1 Oct 21 Johnson David Lee Common Stock Option exercise Acquire M No No 0 4,375 0 41,242
1 Oct 21 Johnson David Lee RSU Common Stock Option exercise Dispose M No No 0 4,375 0 4,375
9 Sep 21 Morrison Scott W Common Stock Sell Dispose S No No 30.2089 4,800 145K 3,037
1 Sep 21 Carrie Krehlik Stock Option Common Stock Grant Acquire A No No 29.85 49,600 1.48M 49,600
1 Sep 21 Carrie Krehlik RSU Common Stock Grant Acquire A No No 0 42,400 0 42,400
1 Sep 21 Carrie Krehlik RSU Common Stock Grant Acquire A No No 0 32,240 0 32,240
1 Sep 21 Choi Jung Common Stock Payment of exercise Dispose F No No 29.85 1,370 40.89K 183,887
1 Sep 21 Choi Jung Common Stock Option exercise Acquire M No No 0 2,762 0 185,257
1 Sep 21 Choi Jung RSU Common Stock Option exercise Dispose M No No 0 2,762 0 19,340

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 191 212 -9.9%
Opened positions 20 27 -25.9%
Closed positions 41 42 -2.4%
Increased positions 80 60 +33.3%
Reduced positions 54 95 -43.2%
13F shares
Current Prev Q Change
Total value 2.27B 2.78B -18.4%
Total shares 64.72M 65.87M -1.7%
Total puts 253.9K 424.8K -40.2%
Total calls 1.72M 443.8K +287.0%
Total put/call ratio 0.1 1.0 -84.6%
Largest owners
Shares Value Change
JHG Janus Henderson 6.17M $216.01M +4.9%
BAC Bank Of America 6.14M $214.86M -1.1%
Vanguard 5.86M $205.31M +5.1%
BLK Blackrock 5.77M $202.08M +37.6%
Perceptive Advisors 4.15M $145.43M -17.9%
TROW T. Rowe Price 3.76M $131.68M -2.9%
Baker Bros. Advisors 3.22M $112.68M 0.0%
STT State Street 2.3M $80.58M +24.3%
BEN Franklin Resources 2.26M $79.01M +3.0%
Point72 Asset Management 2.06M $72.2M +55.5%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 5.77M +1.58M +37.6%
FMR 1.44M -1.47M -50.4%
Pictet Asset Management 1.15M -1.38M -54.5%
Citadel Advisors 0 -1.1M EXIT
Perceptive Advisors 4.15M -905.95K -17.9%
Point72 Asset Management 2.06M +736.12K +55.5%
JPM JPMorgan Chase & Co. 57.92K -690.7K -92.3%
Samlyn Capital 0 -568.18K EXIT
Frontier Capital Management 340.43K -545.87K -61.6%
STT State Street 2.3M +449.42K +24.3%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Good
New words: Columbia, fa, ir, onForm, onset, top
Removed: generation, resumption, salary, Topic

Patents

APP
Utility
Substituted Benzaldehyde Compounds and Methods for Their Use In Increasing Tissue Oxygenation
23 Sep 21
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
APP
Utility
Tablets Comprising 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
16 Sep 21
Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets.
APP
Utility
Process for Synthesizing 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
16 Sep 21
Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes.
GRANT
Utility
Azaindole compounds as histone methyltransferase inhibitors
7 Sep 21
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease).
APP
Utility
Dosing Regimens for 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
2 Sep 21
Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.